[Retracted] LncRNA-PAX8-AS1 Silencing Decreases Cell Viability, Enhances Apoptosis, and Suppresses Doxorubicin Resistance in Myeloid Leukemia via the miR-378g/ERBB2 Axis

Figure 4

MiR-378g was directly targeted by PAX8-AS1, and lowly expressed in refractory/recurrent AML patients and ADM-resistant AML cells. (a) The sequence alignment between miR-378g and PAX8-AS1 was conducted using Starbase. (b) and (c) The interaction between miR-378g and PAX8-AS1 was validated by a dual-luciferase reporter assay. (d) MiR-378g expression in bone marrow samples from refractory/recurrent AML patients, chemo-sensitive AML patients, and healthy volunteers was analyzed by qRT-PCR. (e) MiR-378g expression in HL60 and HL60/ADM cells was analyzed by qRT-PCR. or or or ; vs. MC; ^ξ vs. IC; ^Δ vs. HL60; ^# vs. healthy volunteer; ^∧ vs. refractory/recurrent patients (AML: acute myeloid leukemia; ADM: doxorubicin; WT: wild-type; MUT: mutant type; qRT-PCR: quantitative reverse transcription-polymerase chain reaction; MC: miR-378g mimic; M: mimic control; IC: miR-378g inhibitor; I: inhibitor control; PAX8-AS1: PAX8 antisense RNA 1).

(a)

(b)

(c)

(d)

(e)